Galderma Demonstrates Injectable Aesthetics Leadership in Medication-Driven Weight Loss With New Research and First International Consensus-Based Guidelines
Galderma, the pure-play dermatology category leader, is pioneering new research into the impact of medication-driven weight loss on the skin and the importance of factoring in aesthetic treatment goals during the patient’s journey, as well as the first international consensus-based guidelines from global experts on how to treat this patient population.
Today, at the International Master Course on Aging Science (IMCAS) 2025 annual congress, Galderma will also host a first-of-its-kind masterclass on this topic with international aesthetics experts. Titled “Managing Facial Changes in Patients with Medication-Driven Weight-Loss”, the session will be the opportunity to discuss strategies for managing facial changes in this patient population in clinical practice.
While the rates and stages of adoption differ worldwide, the use of prescription weight loss medications is set to increase globally, with $100 billion sales globally forecasted by 2030, which will have a considerable impact on aesthetics for both patients and healthcare professionals3. With 62% of patients using glucagon-like peptide-1 (GLP-1) getting aesthetic treatment following a healthcare professional recommendation1, there is a clear need for guidance on how to treat this new patient population.
First international consensus-based guidelines
Recognizing the significance and broad impact of prescription weight loss medications, Galderma commissioned the Delphi study to address the need for high-quality research in this area and help establish clinical guidelines for identifying and managing the unique needs of this patient population. This international, multidisciplinary study — incorporating patient interviews, market research, literature reviews, and insights from global experts with extensive experience in treating medication-driven weight loss patients — culminated in a global consensus on key criteria, expert perspectives, and treatment prioritization, all supported by real-world case studies2. These novel consensus guidelines, submitted for publication as the first international consensus-based guidelines from global experts on how to treat this patient population, will be presented by Dr. Andreas Nikolis, during a focus session on “Rapid facial volume loss: causes and consequences” on January 31st, 2025 in the Grand Amphi.
Additionally, Galderma has surveyed more than 1,000 male and female respondents using weight loss medications, aged between 25-65 across the United States, Brazil, Europe and the Middle East1. The focus is understanding the anatomical and aesthetic impact of medication-driven weight loss on the skin, to help equip healthcare professionals to guide patients effectively along their weight loss and aesthetics journey, based on their unique needs.
“With 23% of patients who are already or plan to undergo specific aesthetic treatments, we are now witnessing the emergence of a distinct patient population — those who have undergone significant weight loss and are now seeking complementary aesthetic care. With unique needs, these patients require a thoughtful, integrated approach from healthcare providers. Galderma’s cutting-edge research plays a pivotal role in equipping healthcare providers with the knowledge they need to stay at the forefront of this shift. By addressing these patients' specific concerns from the outset, we can provide a more holistic, tailored approach that enhances both physical transformation and overall well-being.” DR. ANDREAS NIKOLIS, M.D., PH.D., FRCSC, BOARD-CERTIFIED PLASTIC SURGEON MONTREAL, CANADA |
Medication-driven weight loss can lead to a myriad of facial changes, from dry or dull skin to sagging and a gaunt, hollowed-out appearance, as well as alterations in facial structure and balance4. Nearly half (48%) of respondents report significant facial changes due to weight loss treatment1. Menopausal women, in particular, experience higher levels of sagging skin, a slimmer face, and less radiant skin1. Loose or sagging skin on the face and neck is often noted after some weight loss, with facial changes typically observed 3-6 months following treatment (45%), and sometimes as early as 1-2 months (28%)1. These changes occur for several reasons: the loss of fat that typically stretches and cushions the skin, contributing to a youthful appearance, can lead to volume depletion and sagging1. Additionally, the reduction of collagen, elastin, and other essential nutrients can affect skin quality, facial definition, and contouring1.
60% of aesthetic users have undergone treatments to address these effects, while one third of aesthetic considerers would have taken additional measures to prevent skin changes if they had known about the effects on the skin prior to starting their weight loss journey1.The data further reveals that a significant barrier to pursuing aesthetic treatments is the lack of education and information, affecting both current and potential aesthetic users, regardless of their geographical location or stage in the weight loss process1. Further, more than 60% of patients experiencing medicine-driven weight loss show a strong interest in a dual-expertise service that integrates medical and aesthetic professionals to support them during their journey1.These findings from Galderma’s research show that a new, holistic approach to weight loss planning could better support this specific patient population and the healthcare professionals who treat them.
“Galderma is committed to leading the way in understanding the impact of medication-driven weight loss on the skin. As the dermatology category leader, we know that this is not a one size fits all approach. With our deep skin knowledge, aesthetic expertise and individualized treatment approach, Galderma is uniquely positioned to support this evolution and help patients achieve the radiant glow and appearance that they desire.” GERRY MUHLE HEAD GLOBAL OF PRODUCT STRATEGY GALDERMA |
Specifically, 48% of respondents in the study reported that they would undergo Sculptra® treatment and 41% would undergo Restylane® treatment, to address the changes experienced on their face as a result of weight loss treatment1, demonstrating the need for different aesthetic treatments that address the impact on their skin throughout their weight loss journey.
About Galderma
Galderma (SIX: GALD) is the pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body’s largest organ – the skin – meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we are in shapes our lives, we are advancing dermatology for every skin story. For more information: www.galderma.com.
References:
1 Galderma MAC Research. 2024
2 Nikolis A, Enright KM, Fabi S, Somenek M, Avelar L, Franco J, Haddad A, Angelo-Kathar M, Huang J, Safran T, Prygova I, Dayan S. Consensus statements on managing aesthetic needs in prescription medication-driven rapid weight loss patients: An international, multidisciplinary Delphi study. IMCAS 2025.
3 JP Morgan report. The increase in appetite for obesity drugs. November 2023
4 Humphrey CD, Lawrence AC. Implications of Ozempic and other GLP-1 receptor agonists for facial plastic surgeons. Facial Plast Surg. 2023;39:719-721
View source version on businesswire.com: https://www.businesswire.com/news/home/20250129028652/en/
Contacts
For further information:
Christian Marcoux, M.Sc.
Chief Communications Officer
christian.marcoux@galderma.com
+41 76 315 26 50
Sébastien Cros
Corporate Communications Director
sebastien.cros@galderma.com
+41 79 529 59 85
Emil Ivanov
Head of Strategy, Investor Relations, and ESG
emil.ivanov@galderma.com
+41 21 642 78 12
Jessica Cohen
Investor Relations and Strategy Director
jessica.cohen@galderma.com
+41 21 642 76 43
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Alpha Blue Ocean Group Announces the Launch of its Investment Banking Service Provider Division: ABO Transaction Advisory Services. Pierre Vannineuse Steps Down as CIO of ABO’s Investment Division to Lead ABO Transaction Advisory Services Full Time21.2.2025 15:00:00 CET | Press Release
ABO Group, a market leader in Europe for PIPE deals and complex public cross border M&As, announces the establishment of Alpha Blue Ocean Transaction Advisory Services LTD ("ABO-TAS"), a new division dedicated to offering Public Listing Advisory, Capital Raise Advisory, Non-Deal Roadshows, M&A, Management Consulting, Restructuring Advisory and other transaction advisory services. ABO TAS is fully segregated and separate from the Alpha Blue Ocean Group’s Investment Division (which carries out the traditional investment activities of the ABO Group). ABO Group’s investment banking services will leverage the decades of combined experience of the ABO TAS team in investment banking, Public ECM and DCM and most notably structured PIPEs and complex cross border transactions. On the consulting side, the ABO TAS team is dedicated to help businesses reach their maximum potential by capturing synergies between companies and its broad network of established relationships. To spearhead this initiati
Erectile Dysfunction: The PelviTouch Revolution Comes From DEKA’s Italian Technology21.2.2025 14:30:00 CET | Press Release
DEKA Laser, a subsidiary of El.En. S.p.A., a company operating in the Laser and Energy-Based Devices market, listed on Borsa Italiana’s Euronext STAR Milan (“STAR”), and a global leader in medical technologies, has presented its latest innovative therapy, PelviTouch, for the treatment of erectile dysfunction, at the European Society for Sexual Medicine (ESSM) congress. This technology was initially developed, with great success, for the treatment of urinary incontinence for both sexes, and it has now been optimized and specialized by DEKA’s research and development team to improve men’s intimate health, with effective treatments aimed specifically at erectile dysfunction, a field in which the Italian company is an absolute pioneer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250221055364/en/ PelviTouch Therapy Presentation at ESSM Congress (Photo by DEKA) Paolo Salvadeo, DEKA’s CEO and El.En. S.p.A.’s General Manager, has
REPLY: Go Reply and Sprint Reply Automate the Creation of Clinical Study Reports for Dr. Willmar Schwabe with AI21.2.2025 11:01:00 CET | Press Release
Go Reply, a leading Google Cloud Premier Partner, together with Sprint Reply, the Reply Group’s expert in strategic consulting and digital transformation, has developed an AI-driven tool for the pharmaceutical company Dr. Willmar Schwabe that streamlines the preparation of clinical study reports and ensures compliance with the highest scientific standards. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250221805824/en/ By combining Go Reply's expertise in Google technologies with Sprint Reply’s ability to transform business models, a cutting-edge solution has been created that allows Dr. Willmar Schwabe's team to focus on what really matters: advancing research for innovative medicines to improve public health. (Graphic: Business Wire) To obtain marketing authorisation for its high-quality herbal drugs, Dr. Willmar Schwabe must rigorously test their efficacy, safety and tolerability in clinical trials. By leveraging the powe
KKR Invests in Stockholm Multifamily Housing Development Led by Reliwe and Derome21.2.2025 08:10:00 CET | Press Release
Global investment firm KKR today announced the agreement with leading Swedish developers Reliwe and The Derome Group for the forward-purchase of three multifamily properties currently under development in Haninge, located just south of the Stockholm city center. The investment is being made by KKR's European Real Estate strategy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250220298047/en/ Credit: Reliwe / Lindberg Stenberg Arkitekter AB The development is comprised of three new properties totaling 382 residential units, expected to be completed between late 2026 and early 2027. Leading Swedish property developer Reliwe is overseeing the development, which includes two timber construction properties being built by Derome, a leading industrial business, and a third traditional concrete construction asset built to a high specification. The development is located adjacent to a bus terminal and railway station, offering excel
Digital Prosperity Awards Winners Announced at 4 th General Assembly of the Digital Cooperation Organization20.2.2025 23:09:00 CET | Press Release
The Digital Cooperation Organization (DCO), the world's first standalone international intergovernmental organization focusing on the acceleration of the growth of an inclusive and sustainable digital economy, has unveiled the winners of the Digital Prosperity Awards at a ceremony held at its 4th General Assembly gala dinner hosted by the Hashemite Kingdom of Jordan, in the Dead Sea. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250220587577/en/ Digital Prosperity Awards winners announced at 4th General Assembly of the Digital Cooperation Organization (Photo: AETOSWire) Attended by high-level delegations from DCO’s 16 Member States, as well as DCO’s Observers, Partners, and distinguished guests, the Awards aim to acknowledge exceptional initiatives in adopting best practices, policies, and strategies to accelerate digital transformation in their respective countries. The objective is to accelerate digital economic advanceme
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom